证券日报网讯 11月20日晚间，达嘉维康发布公告称，公司近日收到持股5%以上股东、董事钟雪松先生 出具的《关于提前终止股份减持计划的告知函》，获悉钟雪松先生于2025年9月1日至2025年11月20日期 间，通过集中竞价交易方式累计减持公司股份2，050，700股，占公司总股本的1.00%，其持股数量由 19，288，356股减少至17，237，656股，持有公司股份占公司总股本比例由9.39%降低至8.39%。钟雪 松先生决定提前终止本次股份减持计划，未完成减持的股份在剩余减持计划期间内将不再减持。 （编辑 姚尧） ...

北京商报讯(记者丁宁)11月20日晚间，达嘉维康（301126）发布公告称，公司近日收到持股5%以上股 东、董事钟雪松出具的《关于提前终止股份减持计划的告知函》，获悉钟雪松于9月1日至11月20日期 间，通过集中竞价交易方式累计减持公司股份205.07万股，占公司总股本的1%，其持股数量减少至 1723.77万股，持有公司股份占公司总股本比例由9.39%降低至8.39%。钟雪松决定提前终止本次股份减 持计划，未完成减持的股份在剩余减持计划期间内将不再减持。 ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Core Viewpoint - The company announced that a major shareholder, Mr. Zhong Xuesong, has decided to terminate his share reduction plan ahead of schedule, having already reduced his holdings by 2,050,700 shares, which is 1.00% of the total share capital [1] Summary by Relevant Sections - **Shareholder Activity** - Mr. Zhong Xuesong reduced his shareholding from 19,288,356 shares to 17,237,656 shares, decreasing his ownership percentage from 9.39% to 8.39% [1] - The reduction occurred between September 1, 2025, and November 20, 2025, through centralized bidding transactions [1] - **Reduction Plan Status** - The share reduction plan has been terminated early, and no further shares will be sold during the remaining period of the plan [1]

格隆汇11月20日丨达嘉维康(301126.SZ)公布，公司近日收到持股5%以上股东、董事钟雪松先生出具的 《关于提前终止股份减持计划的告知函》，获悉钟雪松先生于2025年9月1日至2025年11月20日期间，通 过集中竞价交易方式累计减持公司股份2,050,700股，占公司总股本的1.00%，其持股数量由19,288,356 股减少至17,237,656股，持有公司股份占公司总股本比例由9.39%降低至8.39%。钟雪松先生决定提前终 止本次股份减持计划，未完成减持的股份在剩余减持计划期间内将不再减持。 ...

达嘉维康公告，持股5%以上股东兼董事钟雪松原拟2025年9月1日至11月30日减持不超350万股（占 1.70%）。截至2025年11月20日已通过集中竞价减持205.07万股，减持均价12.53元/股，占1.00%，持股 数由1928.84万股降至1723.77万股，持股比例由9.39%降至8.39%。钟雪松决定提前终止本次减持计划， 剩余期间不再减持。 ...

湖南达嘉维康医药产业股份有限公司 关于持股 5%以上股东、董事提前终止股份减持计划的公告 公司持股 5%以上股东、董事钟雪松保证向本公司提供的信息真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：301126 证券简称：达嘉维康 公告编号：2025-076 1 二、其他相关说明 1、5%以上股东、董事钟雪松先生本次减持符合《中华人民共和国公司法》《中 华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《上市公司股东减 持股份管理暂行办法（2025 年修订）》《上市公司董事和高级管理人员所持本公司 股份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东 及董事、高级管理人员减持股份（2025 年修订）》等法律法规、部门规章及规范性 文件的规定。 2、5%以上股东、董事钟雪松先生的本次减持计划已按照相关规定进行了预披 露。截至本公告披露日，钟雪松先生减持股份情况与此前已经披露的减持计划一致， 不存在违反已披露的减持计划及相关承诺的情形。截至本公告披露日，本次减持计 划提前终止，未完成减持的股份在剩余减持计划期间内将不再减持。 3、截至本公告披露日，钟雪松先生严格遵守 ...

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Core Insights - The company, Dajia Weikang, reported that as of November 10, 2025, the number of shareholders is 15,783 [2] Company Summary - Dajia Weikang has engaged with investors through an interactive platform, providing updates on shareholder numbers [2] - The reported figure of 15,783 shareholders indicates a potential growth in investor interest and engagement [2]

Core Viewpoint - The company, Dajia Weikang, announced that its subsidiary's Oseltamivir phosphate granules did not qualify for the current centralized procurement due to a lack of two years of production experience for similar formulations [1] Group 1 - The company is actively preparing for market access and expansion efforts for Oseltamivir phosphate granules [1] - The goal is to increase coverage in grassroots markets to benefit more patients [1]